

# SPECTRUM PHARMACEUTICALS, INC.

## REDEFINING CANCER CARE



**S**pectrum Pharmaceuticals, Inc., is a rapidly growing small biotechnology company headquartered in Henderson, Nevada. The company is fully integrated with expertise both in drug development and commercialization.

### Dedicated to Oncology

For over a decade, Spectrum Pharmaceuticals has been dedicated to advancing oncology treatments with passion and commitment. Through our commercial, research, and business development activities, we strive to make a lasting impact on bettering the treatment of cancer.

Over 17,000 patients and their families have been impacted and treated with Spectrum's products. We are embarking upon the most important growth opportunity in Spectrum's history. Our endeavors and our goals are important to us, but they mean even more to thousands of cancer patients, employees, and shareholders.

### Business Development

2014 was an important year for the Company. We were able to secure two partners to market our drugs in important regions, such as greater China and India. In September, we granted CASI Pharmaceuticals, Inc. (NASDAQ: CASI) the exclusive rights for greater

China to distribute three of our drugs, two of which are already commercialized in the U.S., ZEVALIN®, MARQIBO® and EVOMELA®, which is under FDA review. In December, we out-licensed ZEVALIN rights for India to Dr. Reddy's Laboratories, Ltd. We continue to look for opportunities to add to our strong pipeline and product portfolio, as well as for partners to better develop Spectrum's current assets.

### Advancing a Pipeline for Cancer Patients

2015 should be a pivotal year for several drugs in our pipeline. We have made tremendous progress in the development of SPI-2012, a long-acting white blood cell stimulating drug. In February 2015, Spectrum in-licensed Pozotinib, a pan-HER inhibitor in Phase 2 clinical trials from Hanmi Pharmaceutical Co., Ltd. We are especially excited about the prospects of this drug in breast cancer, where the early clinical data is very strong. EVOMELA is a propylene glycol-free formulation of melphalan with improved stability compared to the approved versions of melphalan. Apaziquone is a late-stage bladder cancer drug with promising clinical data and acceptable safety that could satisfy significant unmet medical needs.

We are grateful for your continued support in achieving our goals of bringing important drugs to cancer patients. ■